The aim of this report was to assess the added benefit of enzalutamide compared with best supportive care (BSC) as appropriate comparator therapy (ACT) in men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel chemotherapy.
http://ift.tt/2t1YbX9
Τετάρτη 14 Ιουνίου 2017
Enzalutamide -- Benefit Assessment According to §35a Social Code Book V [Internet].
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Summary Insulinomas are rare neuroendocrine tumours that classically present with fasting hypoglycaemia. This case report discusses an un...
-
The online platform for Taylor & Francis Online content New for Canadian Journal of Remote Sen...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου